Outcomes with non-small cell lung cancer and brain-only metastasis
Sabine Schmid(University of Bern), David Shultz(University of Toronto), Khaleeq Khan(Princess Margaret Cancer Centre), Evan Strom(Princess Margaret Cancer Centre), M. Catherine Brown(University Health Network), Adrian G. Sacher(Princess Margaret Cancer Centre), Joshua Herman(University of Toronto), Amir Sabouhanian(Princess Margaret Cancer Centre), Luna Jia Zhan(University Health Network), Frances A. Shepherd(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), Wei Xu(University Health Network), Sierra Cheng(Princess Margaret Cancer Centre), Natasha B. Leighl(University Health Network), Preet Walia(University Health Network), Devalben Patel(University Health Network), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Penelope A. Bradbury(University Health Network), M. Chowdhury(Princess Margaret Cancer Centre)
Cited by 2
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k